

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Diagnostics Advisory Committee (DAC)

Minutes of the Meeting on Wednesday 4 July

Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BD

PRESENT:

Standing Committee members:

Professor Adrian Newland (Chairman)
Professor Chris Hyde
Mr Christopher Wiltsher
Dr Diego Ossa
Professor Ian Cree
Ms Margaret Ogden
Professor Mark Sculpher
Professor Noor Kalsheker
Dr Paul Collinson
Mr Paul Weinberger
Dr Simon Fleming
Dr Steve Thomas
Dr Sue Crawford
Dr Trevor Cole

Standing Committee apologies:

Dr Erika Denton
Professor Lisa Hall
Dr Mark Kroese
Dr Richard Nicholas
Professor Ron Akehurst
Mr Stuart Saw

Depth of anaesthesia monitors – BispectralIndex(BIS), E-Entropy and Narcotrend-Compact M

Specialist Committee members:

Dr Andrew Smith
Dr David Smith
Dr John Andrzejowski
Mr John Hitchman
Professor Michael Wang

Specialist Committee members apologies:

Professor Anthony Fisher

In attendance: DAP staff

Nick Crabb, Associate Director
Hanan Bell, Technical Adviser
Sarah Byron, Technical Analyst
Frances Nixon, Technical Analyst
Farouk Saeed, Technical Analyst
Jackson Lynn, Project Manager
Bushra Hussain, Administrator
David Lyons, Temporary Administrative Support

External Assessment Group representatives – Southampton Health Technology Assessments Centre (SHTAC)

Jeremy Jones
Jonathan Shepherd

Observing

Andy Stainthorpe, Associate Director, Patient Access Schemes Liaison Unit
Chris Pomfrett, Technical Adviser, Medical Technologies Evaluation Programme
Helen Barnett, Senior Medical Editor
Laura Norburn, Project Manager, Patient and Public Involvement Programme
Leeza Osipenko, Senior Scientific Adviser
Sarah Gage, Coordinator, Meetings in Public

Note: The order in which the Committee took items of business at the meeting differed from the agenda. The minutes record the actual sequence of items, numbered according to the agenda.

**PART 1 AND PART 2 (open and closed parts of the meeting).
10.30am – Part 1 open session commenced.**

1. Introduction to the meeting

The Chair welcomed Committee members and observers.

The Chair welcomed representatives from Coviden UKI & Norden, GE Healthcare Clinical Systems (UK) Ltd and Narcotrend to the the meeting.

Apologies were noted.

2. Code of conduct for members of the public attending the meeting

The Chairman explained the code of conduct to the members of the public attending this meeting.

3. Any other business

No other business was offered.

4. Minutes from the last Committee meeting

The Committee agreed the minutes from the Wednesday 6 June Committee meeting.

5. NICE's advisory body guide to declaring a conflict of interest

The Chairman drew the Committee's attention to NICE's Advisory Body Quick Guide for declaring conflicts of interest, the selection and routing criteria and the equalities statement.

6. Depth of anaesthesia monitors –BispectralIndex(BIS), E-Entropy and Narcotrend-Compact M - Draft Guidance

Part 1 – Open session

The Chair informed all attendees that Professor Ron Akehurst has declared interests and is conflicted therefore he is not taking part in this meeting.

The Chair requested any conflicts of interest to be stated. Dr David Smith and Dr John Andrzejowski declared their conflicts, this did not mean they were unable to participate in the meeting.

The Chair introduced Technical Analyst, Sarah Byron to discuss with the committee the consideration of public consultation comments on Depth of anaesthesia monitors –BispectralIndex(BIS), E-Entropy and Narcotrend-Compact M

The Committee was asked if there were any specific equalities to consider in relation to this technology.

The Chair asked the representatives of the manufacturers to comment on any matters of factual accuracy.

There were no public attendees.

The Chair then thanked the experts and manufacturer representatives for their attendance, participation and contribution to the Assessment and they left the meeting.

The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

Part 2 – closed session

The Committee instructed the technical team to prepare the Diagnostics Consultation Document (DCD) in line with their decisions.

SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption

Specialist Committee members:

Dr Matthew Brookes
Dr Annelies Maenhout
Professor John McLaughlin
Dr Kevin Bradley
Dr Nick Read
Dr Richard Thompson

External Assessment Group representatives: Kleijnen Systematic Reviews Ltd

Hans Severens
Maiwenn Al
Marie Westwood

**PART 1 AND PART 2 (open and closed parts of the meeting).
13:15 – Part 1 open session commenced.**

7. Introduction to the meeting

The Chair welcomed Committee members and observers.

The Chair welcomed the representative from GE Healthcare, Manufacturer to the meeting.

Apologies were noted

8. Any other business

No other business was offered.

9. NICE's advisory body guide to declaring a conflict of interest

The Chairman drew the Committee's attention to NICE's Advisory Body Quick Guide for declaring conflicts of interest, the selection and routing criteria and the equalities statement.

The Chair informed all attendees that Professor Ron Akehurst has declared interests and is conflicted therefore he is not taking part in this meeting.

The Chair asked Committee members to declare any relevant interests.

10. SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption - Final Recommendations

The Chair introduced the following presentations:

The Chair introduced presentations from the Lead Team members:

- Professor Chris Hyde – Standing Committee Member
- Dr Matthew Brookes – Specialist Committee Member

The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of SeHCA (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption

The Chair asked the Committee to consider any Equality issues in relation to these technologies.

The Chair asked the representatives of the manufacturer to comment on any matters of factual accuracy.

There was one public member who attended this meeting.

The Chair then thanked the manufacturer representative for their attendance, participation and contribution to the Assessment and they left the meeting

The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

Part 2 – closed session

The Committee instructed the technical team to prepare the Diagnostics Consultation Document (DCD) in line with their decisions.

Date, time and venue of next meeting

Tuesday 4 September, 10:00 at National Institute for Health and Clinical Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BD